Fig. 3: Superior efficacy of intravenous (IV) to intravitreal (IVT) delivery of anti-PRL3 antibody in the recovery of CNV lesions by attenuating SRC phosphorylation.
From: PRL3-zumab as an anti-angiogenic therapy in neovascular eye diseases
a Experimental timeline of drug treatment (IVT and IV) in laser-induced CNV model. (Created in BioRender72). b Representative FFA images of PBS/mouse IgG and anti-PRL3 antibody treated groups with IVT and IV as delivery routes (Day 7 versus Day 1). c Quantification of the % recovery of the CNV lesions after drug treatment. IV treatment of anti-PRL3 antibody showed significant recovery of CNV lesions compared to PBS/IgG control group (anti-PRL3 antibody: 65.3% versus PBS/IgG: −67.7%) and 86% better than IVT delivery of anti-PRL3 antibody (IV: 65.3% versus IVT: 35.1%, p = 0.003). Efficacy of IVT treatment of anti-PRL3 antibody is comparable to that of aflibercept (Aflibercept: 38.1% versus anti-PRL3 antibody: 35.1%). ‘n’ indicates the number of CNV spots used in analysis. d Quantification of the Western blots of choroid-RPE tissues shows the attenuation of SRC phosphorylation (Y416) effected by anti-PRL3 antibody (p = 0.0383) and aflibercept (p = 0.0009) treatments. All images shown are representative and the mean value was calculated using one-way analysis of variance (ANOVA) (mean ± s.d., n ≥ 3 biologically independent samples each). ***P < 0.001; **P < 0.01; *P < 0.05. FFA Fundus Fluorescein Angiography, OCT Optical Coherence Tomography, IVT Intravitreal, IV Intravenous. Source data are provided as a Source Data file.
